Du Jing, Staff Journalist. Beijing

Wenshan Daphne panax pseudoginseng industry press release conference was held on December 2 at the Great Hall of the People, Beijing. 

         Wenshan abounds in biological resources. What's notable, it contributes more than 95% of the national production of panax pseudoginseng. Since the Ninth Five-year Plan Period, the Wenshan Zhuang & Miao Autonomous Prefecture has scaled up investment in development of panax pseudoginseng. In 1999, the prefecture-wide panax pseudoginseng planting area amounted to over 40000 mu (2666.67 hectares), with production of 1.25 million kg. Up to 20 enterprises were engaged in panax pseudoginseng series product processing, involving products of close to 100 varieties. The panax pseudoginseng industry realized gross output value of RMB 400 million yuan, with sales income of RMB 350 million yuan and taxes of RMB 30 million yuan. Development and utilization of panax pseudoginseng is expected to be listed by the Yunnan provincial Party Committee and Provincial Government this year as a major project for implementation of the state's Great West China Development and provincial construction of a green economic power. Go-ahead has been given to the project of China Wenshan Panax Pseudoginseng Industrial Park, covering an area of 1200 mu (80 hectares).

         Among the local panax pseudoginseng product developing & processing enterprises, the Wenshan Daphne Pharmaceutical Co., Ltd. Yunnan is the largest one, whose drug production and quality management have passed GMP certification by the state regulator. So far, they have launched 4 generations, totally 17 varieties, of panax pseudoginseng series products, which are widely sold on the domestic market and Southeast Asian markets. Now, the products are finding way to the European and American market.

(Source: Home page of the December 4, 2000 issue of Dianchi Morning)